HbA(1c) levels in non-diabetic older adults No J-shaped associations with primary cardiovascular events, cardiovascular and all-cause mortality after adjustment for confounders in a meta-analysis of individual participant data from six cohort studies by Schoettker, B et al.
RESEARCH ARTICLE Open Access
HbA1c levels in non-diabetic older adults –
No J-shaped associations with primary
cardiovascular events, cardiovascular and
all-cause mortality after adjustment for
confounders in a meta-analysis of individual
participant data from six cohort studies
Ben Schöttker1,2* , W. Rathmann3, C. Herder4,5, B. Thorand6, T. Wilsgaard7, I. Njølstad7, G. Siganos8, E. B. Mathiesen8,
K. U. Saum1, A. Peasey9, E. Feskens10, P. Boffetta11,12, A. Trichopoulou12, K. Kuulasmaa13, F. Kee14, H. Brenner1
and on behalf of the CHANCES group
Abstract
Background: To determine the shape of the associations of HbA1c with mortality and cardiovascular outcomes in
non-diabetic individuals and explore potential explanations.
Methods: The associations of HbA1c with all-cause mortality, cardiovascular mortality and primary cardiovascular
events (myocardial infarction or stroke) were assessed in non-diabetic subjects ≥50 years from six population-based
cohort studies from Europe and the USA and meta-analyzed. Very low, low, intermediate and increased HbA1c were
defined as <5.0, 5.0 to <5.5, 5.5 to <6.0 and 6.0 to <6.5 % (equals <31, 31 to <37, 37 to <42 and 42 to <48 mmol/mol),
respectively, and low HbA1c was used as reference in Cox proportional hazards models.
Results: Overall, 6,769 of 28,681 study participants died during a mean follow-up of 10.7 years, of whom 2,648 died of
cardiovascular disease. Furthermore, 2,493 experienced a primary cardiovascular event. A linear association with primary
cardiovascular events was observed. Adjustment for cardiovascular risk factors explained about 50 % of the excess risk
and attenuated hazard ratios (95 % confidence interval) for increased HbA1c to 1.14 (1.03–1.27), 1.17 (1.00–1.37) and
1.19 (1.04–1.37) for all-cause mortality, cardiovascular mortality and cardiovascular events, respectively. The six cohorts
yielded inconsistent results for the association of very low HbA1c levels with the mortality outcomes and the pooled
effect estimates were not statistically significant. In one cohort with a pronounced J-shaped association of HbA1c levels
with all-cause and cardiovascular mortality (NHANES), the following confounders of the association of very low HbA1c
levels with mortality outcomes were identified: race/ethnicity; alcohol consumption; BMI; as well as biomarkers of iron
deficiency anemia and liver function. Associations for very low HbA1c levels lost statistical significance in this cohort
after adjusting for these confounders.
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Conclusions: A linear association of HbA1c levels with primary cardiovascular events was observed. For cardiovascular
and all-cause mortality, the observed small effect sizes at both the lower and upper end of HbA1c distribution do not
support the notion of a J-shaped association of HbA1c levels because a certain degree of residual confounding needs
to be considered in the interpretation of the results.
Keywords: Glycated hemoglobin, Cardiovascular disease, Myocardial infarction, Stroke, Mortality, Cohort study,
Meta-analysis
Background
Glycated hemoglobin (HbA1c) is a biomarker for impaired
glucose metabolism and indicates the average blood glucose
concentration over the previous 2–3 months [1]. Non-
diabetic subjects with increased HbA1c, often termed
“pre-diabetes”, do not only have a higher risk for the
development of manifest diabetes mellitus but also for
cardiovascular events and all-cause mortality [2–5].
However, it is unclear how much of the excess risk is
contributed by the impaired glucose metabolism and
how much by simultaneously increased cardiovascular
risk factor levels [6, 7].
With regard to very low HbA1c levels in subjects with-
out diabetes mellitus, the results from population-based
cohort studies are inconsistent. Whereas some authors did
not observe an increased risk or observed a decreased risk
[8–12], others reported an increased risk for cardiovascu-
lar outcomes or death among subjects with HbA1c levels
below 4.0 % (20 mmol/mol) [13], 4.8 % (29 mmol/mol)
[14], 4.9 % (30 mmol/mol) [15] or 5.0 % (31 mmol/mol)
[5, 16–18] compared to subjects from the adjacent higher
HbA1c interval, along with a stronger increase in risk in
non-diabetic subjects with increased HbA1c. Some authors
have called this a J-shaped or U-shaped relationship be-
tween HbA1c and cardiovascular risk or mortality [5, 14,
16–18]. A statistically significant increased cardiovascular
disease risk for non-diabetics with very low HbA1c levels
was for the first time observed in the largest study of this
type to date, the individual participant data meta-analysis
of 24 studies of the Emerging Risk Factors Collaboration
(ERFC) [5]. So far, however, no study has aimed to assess
potential explanations for an increased cardiovascular
risk of non-diabetics with very low HbA1c in a large
consortium. Explanatory hypotheses, proposed in literature,
include:
1) Underweight (as part of the frailty syndrome in
older non-diabetics [19])
2) Inflammation (caused by frequent asymptomatic
hypoglycemic episodes [20])
3) Anemia with or without iron deficiency (because
of abnormalities of erythrocyte indices [21] and
potentially correlated hemoglobin and HbA1c
values [22])
4) High alcohol consumption (inhibiting the
gluconeogenesis in the liver [23] and shortening
the red blood cell lifespan)
5) Liver disease (as a result of high alcohol
consumption [17])
6) Chronic renal failure (reduced red blood cell lifespan
and increased carbamylated hemoglobin affect the
accuracy of HbA1c measurements [24, 25])
7) Hematologic differences according to race/ethnicity
(non-Hispanic black people have a special
hematologic profile [26] and have more frequently
very low HbA1c levels than people of other race/
ethnicity [27]).
The objective of this meta-analysis of individual par-
ticipant data is to investigate whether there is a J-shaped
association of HbA1c levels with cardiovascular events,
cardiovascular mortality and all-cause mortality in non-
diabetic older adults and to explore potential explanations
for a potentially increased risk at very low HbA1c levels.
Methods
Study design and study population
This investigation is a meta-analysis of individual partici-
pant data of six population-based cohort studies: Tromsø
(Norway); ELSA (UK); NHANES (USA); ESTHER
(Germany); KORA (Germany); and SHIP (Germany).
Details of each study’s acronym, recruitment procedure and
data collection are given in Additional file 1. All variables
were harmonized in the framework of the Consortium on
Health and Ageing: Network of Cohorts in Europe and the
United States (CHANCES; www.chancesfp7.eu).
Ethics, consent and permissions
The included studies have been approved by local ethics
committees (see Additional file 1). Written informed
consent has been obtained from all participants included in
the analyzed studies and the studies are being conducted in
accordance with the Declaration of Helsinki.
Inclusion and exclusion criteria
Study participants with missing HbA1c measurements
at baseline were excluded. To make cohorts more
comparable, analyses were restricted to study participants
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aged 50 years and older. Furthermore, to restrict the sam-
ple to subjects without diabetes mellitus, all subjects with
diagnosed diabetes mellitus, missing information about a
diabetes diagnosis and with potential undiagnosed dia-
betes (defined by HbA1c ≥6.5 % (≥48 mmol/mol) [28])
were excluded. The final number of included study partici-
pants from each cohort is shown in Table 1. The sample
sizes differ for the outcomes because subjects lost to
follow-up right after baseline were excluded. Subjects who
died of unknown causes were only excluded for the out-
come “cardiovascular mortality” (ICD-10 code R96–99 or
missing) and subjects with a history of myocardial infarc-
tion (MI) or stroke at baseline were only excluded for the
outcome “primary cardiovascular events”.
Outcome ascertainment
We assessed three outcomes: all-cause mortality; cardio-
vascular mortality; and primary cardiovascular events.
The latter was defined by non-fatal MI, non-fatal stroke
or cardiovascular death during follow-up, while subjects
with a history of MI or stroke before baseline were ex-
cluded. Details about the assessment of the outcomes
are outlined in the cohort descriptions (Additional file
1). In brief, all cohorts ascertained deaths by region- or
country-wide registries. Data for incident non-fatal MI
or stroke cases were available from all cohorts except
NHANES. Diagnoses were based on medical records in
Tromsø, ESTHER and KORA and on participant-reported
physician diagnoses in ELSA and SHIP. If assessed,
ICD-10 codes were used to ascertain cardiovascular
mortality (I00–I99), MI (I21–I23) and stroke (I60–I69).
Measurement of HbA1c
All cohorts measured HbA1c with assays certified by
the National Glycohemoglobin Standardization Program
(NGSP), which are traceable to the assay of the Diabetes
Control and Complications Trial (DCCT). Details about
the assays are given in the cohort descriptions (Additional
file 1).
Covariate assessment
Socio-demographic, lifestyle, anthropometric and history
of disease data were assessed by self-administered ques-
tionnaires or in interviews. In addition to self-reported
information, some studies measured weight and height
and validated the history of MI or stroke by consulting
medical records or registries (Additional file 1: Table S1).
If measured anthropometric data or validated diagnoses
were available, they were used in the analysis and self-
reported information was only used to fill missing infor-
mation. With a modification of the underweight category,
BMI categories of the World Health Organization (WHO)
were applied to define underweight (<20 kg/m2), optimal
BMI (20 to <25 kg/m2), overweight (25 to <30 kg/m2) and
obesity (≥30 kg/m2). The underweight category was ex-
tended for our population of older adults because it has
been previously shown that mortality is already increased
at BMI <20 kg/m2 in individuals aged ≥65 years [29]. Total
cholesterol, high-density lipoprotein (HDL) cholesterol,
C-reactive protein (CRP), serum creatinine, urinary albu-
min and blood hemoglobin were measured for the total
cohorts by routine methods in central laboratories co-
operating with the study centers. Serum creatinine
was not assessed in ELSA, blood hemoglobin was not
measured in ESTHER and urinary albumin was not de-
termined in ELSA and KORA. Subclinical inflammation
was defined by CRP ≥3 mg/L [30] and albuminuria by
urinary albumin ≥20 mg/L [31]. Biomarkers of liver
function (alanine transferase (ALT), aspartate transferase
(AST) and gamma-glutamyl transferase (GGT)) and iron
deficiency (ferritin, transferrin saturation and erythrocyte
protoporphyrin [32]) were only utilized from NHANES
because this was the only study to assess all such indices.
The analytical methods have been described elsewhere
[32, 33]. Race/ethnicity was recorded in NHANES by
four categories: non-Hispanic white; non-Hispanic black;
Mexican-American; and other. The European studies in-
cluded almost exclusively Caucasians and further differen-
tiation of race/ethnicity in these cohorts was waived.
The different school-leaving qualifications of the coun-
tries were translated into the number of school years
attended and three categories of education were devised
(≤9 years, 10–12 years and ≥13 years). Reported average
amounts of consumed wine, beer and spirits were con-
verted into grams of pure ethanol per day and summed.
Although the WHO reports comparable figures of con-
sumed alcohol volumes per inhabitant in the European
Union and United States [34], the calculated numbers
from the cohorts diverged. In order to further standardize
alcohol consumption, cohort and sex-specific percentiles
(pct.) were calculated according to the average daily
ethanol consumption and the following three categories
of relative alcohol consumption were built: abstainer or
low alcohol consumption (≤50th pct.); moderate alcohol
consumption (>50th to <90th pct.); and high alcohol
consumption (≥90th pct.). Vigorous physical activity was
harmonized as a dichotomous variable (Yes or No) from
questions regarding whether study participants perform
physical activity that causes sweating (e.g. sports).
Statistical analyses
Based on subject matter knowledge, HbA1c levels were
categorized in 0.5 % intervals and classified as “very
low” (<5.0 % (31 mmol/mol)), “low” (5.0 to <5.5 % (31
to <37 mmol/mol)), “intermediate” (5.5 to <6.0 % (37
to <42 mmol/mol)) and “increased” (6.0 to <6.5 % (42
to <48 mmol/mol)). Individuals with low HbA1c levels
were used as the reference group in all analyses. Means or
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Table 1 Baseline characteristics of participants without diabetes mellitus and number of events during follow-up of included cohort
studies
Baseline characteristic Unit ESTHER SHIP ELSA Tromsø KORA NHANES
Baseline years for this analysis 2000–2002 1997–2001 2004–2005 1994–1995 1999–2001 1988–1994
Total sample size 7,982 1,777 5,262 6,045 1,850 5,778
Age Years 61.8 (6.6) 63.4 (8.3) 65.8 (9.7) 61.6 (7.0) 61.7 (7.1) 67.9 (11.0)
Age ≥65 years % 2,481 (31.1) 733 (41.3) 2,410 (45.8) 1,958 (32.4) 645 (34.9) 3,157 (54.6)
Male sex % 3,476 (43.6) 905 (50.9) 2,334 (44.4) 2,550 (42.2) 929 (50.2) 2,774 (48.0)
Race/ethnicity
Non-Hispanic white % N/A N/A N/A N/A N/A 3,428 (60.3)
Non-Hispanic black % N/A N/A N/A N/A N/A 1,088 (18.8)
Mexican-American % N/A N/A N/A N/A N/A 997 (17.3)
Other % N/A N/A N/A N/A N/A 211 (3.7)
School education
≤9 years % 5,743 (73.5) 975 (55.2) 968 (19.0) 3,228 (53.8) 322 (17.5) 2,238 (39.1)
10–12 years % 1,671 (21.4) 443 (25.1) 3,137 (61.6) 1,773 (29.5) 1,156 (62.7) 2,147 (37.5)
≥13 years % 398 (5.1) 348 (19.7) 992 (19.5) 1,005 (16.7) 367 (19.9) 1,343 (23.5)
BMI kg/m2 27.3 (4.2) 28.2 (4.4) 27.5 (4.6) 25.9 (3.8) 28.1 (4.2) 26.8 (5.2)
BMI category
Underweight % 146 (1.8) 29 (1.6) 141 (2.8) 239 (4.0) 21 (1.1) 361 (6.3)
Optimal weight % 2,249 (28.2) 389 (21.9) 1,356 (26.9) 2,360 (39.1) 389 (21.2) 1,835 (31.9)
Overweight % 3,816 (47.9) 832 (46.9) 2,247 (44.6) 2,603 (43.2) 907 (49.3) 2,251 (39.2)
Obese % 1.763 (22.1) 525 (29.6) 1,296 (25.7) 831 (13.8) 522 (28.4) 1,303 (22.7)
Smoking
Never % 3,974 (51.1) 942 (54.6) 2,390 (45.8) 1,949 (32.3) 969 (53.4) 2,583 (44.7)
Former % 2,479 (31.9) 486 (28.2) 1,922 (36.8) 2,184 (36.2) 568 (31.3) 1,956 (33.9)
Current % 1,319 (17.0) 298 (17.3) 905 (17.4) 1,907 (31.6) 279 (15.4) 1,239 (21.4)
Relative alcohol consumption
Abstainer or low % 3,851 (53.2) 848 (50.5) 2,537 (50.1) 2,394 (51.7) 1,005 (54.6) 3,410 (64.2)
Moderate % 2,650 (36.6) 655 (39.0) 2,024 (39.9) 1,745 (37.7) 638 (34.6) 1,325 (24.9)
High % 741 (10.2) 177 (10.5) 508 (10.0) 490 (10.6) 199 (10.8) 580 (10.9)
Vigorous physical activity % 3,452 (43.4) 905 (51.5) 2,232 (42.4) 2,043 (34.2) 819 (44.5) 2,204 (38.2)
Total cholesterol mmol/L 5.7 (1.3) 6.1 (1.2) 6.0 (1.2) 6.8 (1.3) 6.3 (1.1) 5.7 (1.1)
HDL cholesterol mmol/L 1.4 (0.4) 1.5 (0.4) 1.5 (0.4) 1.6 (0.4) 1.5 (0.4) 1.4 (0.4)
Subclinical inflammation % 2,786 (35.5) 492 (28.8) 1,827 (35.0) 1,079 (20.8) 520 (28.4) 2,187 (38.9)
Serum creatinine nmol/L 79.8 (28.1) 87.1 (18.5) N/A 67.6 (16.0) 76.5 (21.3) 101.6 (29.4)
Albuminuria % 760 (9.6) 331 (21.0) N/A 675 (12.8) N/A 1,166 (22.0)
Hemoglobin g/dL N/A 13.6 (1.2) 14.3 (1.4) 14.1 (1.1) 14.4 (1.2) 13.9 (1.4)
Biomarkers of iron deficiency
Ferritin μg/L N/A N/A N/A N/A N/A 157 (168)
Transferrin saturation % N/A N/A N/A N/A N/A 25.2 (10.6)
Erythrocyte protoporphyrin μmol/L N/A N/A N/A N/A N/A 0.95 (0.56)
Hypertension
No hypertension % 3,270 (41.0) 807 (45.5) 2,526 (48.0) 2,584 (42.8) 849 (46.1) 2,553 (44.2)
Known hypertension or systolic blood
pressure ≥140 to <160 mmHg
% 3,915 (49.1) 593 (33.4) 2,313 (44.0) 2,044 (33.8) 778 (42.2) 2,545 (44.1)
Systolic blood pressure ≥160 mmHg % 796 (10.0) 375 (21.1) 423 (8.0) 1,417 (23.4) 216 (11.7) 679 (11.8)
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proportions with 95 % confidence intervals of baseline
characteristics were calculated in each cohort stratified by
HbA1c category and pooled with a fixed effects model. In
addition to these descriptive statistics, a multivariable
logistic regression model was carried out with HbA1c
category as the dependent variable (with reference to
the low HbA1c group) and the baseline characteristics
of the “full” model as independent variables. The “full”
model comprised the variables of age, sex, race (for
NHANES), BMI, education, smoking, physical activity,
alcohol consumption, total cholesterol, HDL cholesterol,
CRP, blood hemoglobin concentration, serum creatinine,
albuminuria, hypertension, history of MI or stroke and
biomarkers of liver function or iron deficiency. Variables
were modelled continuously or in the categories shown in
Table 2. Blood hemoglobin concentration, urinary albu-
min, serum creatinine and biomarkers of liver function
or iron deficiency were not assessed in all cohorts (see
Table 1) and were excluded from the “full” model for
the respective cohorts.
For being plausible explanations for an association of
very low HbA1c levels with mortality or cardiovascular
outcomes, known cardiovascular/mortality risk factors
should be associated with very low HbA1c levels in the
logistic regression model and with mortality outcomes
in the same direction (i.e. being a risk factor for both very
low HbA1c and mortality). Risk factors of interest were
underweight, subclinical inflammation, blood hemoglobin
concentration (biomarker of anemia), ferritin, transferrin
saturation or erythrocyte protoporphyrin (biomarkers
of iron deficiency), alcohol consumption, albuminuria
(biomarker of renal function), serum creatinine (bio-
marker of renal function), AST, ALT or GGT (biomarkers
of liver function). Furthermore, adding the variables to an
age- and sex-adjusted model for mortality should attenu-
ate the observed association of very low HbA1c with the
Table 1 Baseline characteristics of participants without diabetes mellitus and number of events during follow-up of included cohort
studies (Continued)
History of MI or stroke % 511 (6.5) 140 (7.9) 398 (7.6) 438 (7.3) 97 (5.2) 738 (12.8)
Biomarkers of liver function
GGT U/L N/A N/A N/A N/A N/A 31.6 (45.5)
AST U/L N/A N/A N/A N/A N/A 21.9 (11.8)
ALT U/L N/A N/A N/A N/A N/A 14.7 (10.6)
HbA1c % 5.5 (0.4) 5.4 (0.5) 5.4 (0.3) 5.4 (0.4) 5.6 (0.3) 5.5 (0.5)
Very low (<5.0 % (<31 mmol/mol)) % 476 (6.0) 336 (18.9) 345 (6.6) 626 (10.4) 63 (3.4) 678 (11.7)
Low (5.0 to <5.5 %
(31 to <37 mmol/mol))
% 2,747 (34.4) 546 (30.7) 2,344 (44.6) 2,719 (45.0) 603 (32.6) 1,994 (34.5)
Intermediate (5.5 to <6.0 %
(37 to <42 mmol/mol))
% 3,726 (46.7) 583 (32.8) 2,201 (41.8) 2,323 (38.4) 937 (50.7) 2,272 (39.3)
Increased (6.0 to <6.5 %
(42 to <48 mmol/mol))
% 1,033 (12.9) 312 (17.6) 372 (7.1) 377 (6.2) 247 (13.4) 834 (14.4)
Follow-up
All-cause mortality
Total sample size 7,981 1,777 5,253 6,045 1,850 5,775
Cases (%) 1,069 (13.4) 298 (16.8) 645 (12.3) 1,704 (28.2) 180 (9.7) 2,873 (49.8)
Mean FUP (SD) Years 11.1 (2.1) 9.4 (2.1) 7.0 (1.3) 14.0 (3.8) 8.5 (1.3) 11.4 (4.9)
Cardiovascular mortality
Total sample size 7,943 1,761 5,113 5,987 1,843 5,721
Cases (%) 263 (3.3) 90 (5.1) 174 (3.0) 707 (11.8) 69 (3.7) 1,345 (23.5)
Mean FUP (SD) Years 11.1 (2.0) 9.4 (2.1) 7.0 (1.3) 14.1 (3.8) 8.6 (1.3) 11.4 (4.9)
Cardiovascular events
Total sample size 7,233 1,637 4,462 5,602 1,556 N/A
Cases (%) 595 (8.2) 65 (4.0) 315 (7.1) 1,386 (24.7) 132 (8.5) N/A
Mean FUP (SD) Years 7.1 (2.3) 9.5 (2.0) 5.3 (1.4) 12.6 (4.8) 8.2 (1.7) N/A
Unless indicated otherwise, the table shows proportions (%) for categorical and means (SD) for continuous variables. Numbers shown were drawn from the
unimputed data set. Therefore, numbers do not always add up to the total because of missing values (see Additional file 1: Table S2 for number of missing values
for each variable). ALT, alanine transferase; AST, aspartate transferase; BMI, body mass index; FUP, follow-up; GGT, gamma-glutamyl transferase; HbA1c, glycated
hemoglobin; HDL, high-density lipoprotein; MI, myocardial infarction; N/A, not assessed; SD, standard deviation
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Table 2 Baseline characteristics of subjects without diabetes mellitus by very low and low HbA1c levels and multivariable adjusted
odds ratios for associations of characteristics with very low HbA1c levels. Pooled data from six cohort studies
Characteristic Unit Weighted mean or proportion (%) (95 % CI) Pooled odds ratio (95 % CI)
Very low HbA1c Low HbA1c
(<5.0 %) (5.0 to <5.5 %)
(<31 mmol/mol) (31 to <37 mmol/mol)
(reference group)
Age Years 61.1 (60.8–61.4) 62.2 (62.1–62.4) 0.77 (0.72; 0.81) per 10 years
Male sex % 49.4 (47.4–51.3) 45.0 (44.1–46.0) 1.15 (0.93; 1.42)a
Race/ethnicityb
Non-Hispanic white % 63.3 70.0 Ref
Non-Hispanic black % 20.2 11.8 1.60 (1.21; 2.12)
Mexican-American % 13.7 15.1 0.88 (0.65; 1.17)
Other % 2.8 3.0 0.88 (0.51; 1.53)
School education
≤9 years % 45.5 (43.4–47.6) 45.9 (44.9–46.9) Ref
10–12 years % 36.3 (34.3–38.2) 39.1 (38.1–40.0) 0.98 (0.91; 1.05)
≥13 years % 21.4 (19.8–23.1) 19.0 (18.3–19.8) 1.00 (0.92; 1.09)
BMI category
Underweight % 4.5 (3.7–5.4) 3.9 (3.5–4.3) 1.13 (0.94; 1.35)
Optimal weight % 36.2 (34.3–38.1) 34.6 (33.7–35.5) Ref
Overweight % 44.6 (42.7–46.6) 43.6 (42.7–44.6) 1.02 (0.93; 1.11)
Obese % 16.0 (14.6–17.5) 19.2 (18.5–20.0) 0.82 (0.73; 0.92)
Smoking
Never % 46.4 (44.4–48.4) 45.8 (44.8–46.7) Ref
Former % 35.3 (33.5–37.2) 34.8 (33.9–35.7) 0.94 (0.85; 1.05)
Current % 19.6 (18.0–21.3) 20.0 (19.5–21.1) 0.70 (0.61; 0.81)
Relative alcohol consumption
Abstainer or low % 48.0 (45.9–50.0) 50.9 (49.9–51.9) Ref
Moderate % 36.8 (34.8–38.8) 37.4 (36.4–38.3) 0.93 (0.87; 1.01)
High % 15.7 (14.3–17.3) 12.0 (11.4–12.7) 1.21 (1.10; 1.33)
Vigorous physical activity % 43.6 (41.6–45.5) 42.3 (41.4–43.3) 0.95 (0.86; 1.05)
Total cholesterol mmol/L 5.81 (5.76–5.86) 6.03 (6.01–6.05) 0.85 (0.81; 0.88) per 1 mmol/L
HDL cholesterol mmol/L 1.51 (1.49–1.53) 1.52 (1.51–1.53) 1.13 (1.00; 1.27) per 1 mmol/L
Subclinical inflammation % 27.1 (25.3–28.9) 28.1 (27.2–29.0) 1.02 (0.92; 1.14)
Serum creatinine nmol/L 76.2 (75.5–77.0) 76.4 (76.0–76.8) 1.00 (0.98; 1.03) per 10 nmol/L
Albuminuria % 15.2 (13.6–17.0) 13.3 (12.5–14.1) 0.93 (0.79; 1.10)
Hemoglobin g/dL 14.13 (14.07–14.18) 14.16 (14.14–14.19) 1.06 (0.89; 1.25)a per 1 g/dL
Biomarkers of iron deficiencyb
Ferritin μg/L 210 (268) 152 (148) 1.12 (1.06; 1.18) per 100 μg/L
Transferrin saturation % 27.5 (13.1) 26.0 (10.6) 1.13 (1.03; 1.23) per 10 %
Erythrocyte protoporphyrin μmol/L 1.09 (1.17) 0.93 (0.42) 1.25 (1.14; 1.38) per 0.5 μmol/L
Hypertension
No hypertension % 47.0 (45.1–49.0) 47.0 (46.1–48.0) Ref
Known hypertension or systolic blood
pressure ≥140 to <160 mmHg
% 39.8 (37.9–41.7) 40.2 (39.3–41.1) 1.02 (0.96; 1.10)
Systolic blood pressure ≥160 mmHg % 14.2 (12.9–15.7) 14.0 (13.4–14.7) 1.03 (0.94; 1.13)
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outcome. The described analyses to identify plausible ex-
planatory variables were only conducted in the NHANES
because only this cohort assessed all variables of interest
listed above.
For longitudinal analyses, Cox proportional hazards
regression models were utilized after the proportional
hazards assumption was tested with Schoenfeld residuals
(which was fulfilled). We compared HbA1c categories
with respect to the outcomes all-cause mortality, cardio-
vascular mortality and primary cardiovascular events in
a “simple”, age- and sex-adjusted model and the “full”
model (see list of variables above, except no adjustment
for history of MI or stroke for the outcome “primary
cardiovascular events” because of exclusions).
We used a two-step approach: we first analyzed the
single studies and pooled the results thereafter by meta-
analysis. Meta-analyses were conducted with the statistical
software Comprehensive Meta-Analysis 2.0 (Biostat,
Englewood, NJ, USA). A one-step approach was not
possible because UiT The Arctic University of Norway
did not consent to send individual data of the Tromsø
study to the analyzing center in Heidelberg, Germany.
This was also the reason why a dose-response analysis
with restricted cubic splines could not be conducted in
a pooled data set. Instead, such curves were exemplarily
retrieved from the NHANES with five a priori defined
knots at HbA1c levels of 4.5 %, 5 %, 5.5 % and 6.25 %
and 5.25 % as the reference [35]. Results from the
NHANES are a good approximation for the results from
the total consortium because the NHANES assessed all
potential confounders and dominated the meta-analyses
with its high case numbers.
In meta-analyses, statistical heterogeneity among the
studies was examined with Cochrane’s Q test and the I2
statistic. Fixed effects models were reported unless signifi-
cant heterogeneity was present, taking only the sample
size of the cohorts into account. In the few occasions of
significant heterogeneity, this was indicated and random
effects model results were reported, taking the sample size
of the cohorts and the between-study variance into ac-
count. In the fixed effects model, the weight of the studies
was expressed as the inverse of the variance of the loga-
rithm of the estimated hazard ratio (HR). In the random
effects model, a variation of the inverse-variance method,
invented by DerSimonian and Laird, was applied, which
adjusts for the heterogeneity in the meta-analysis and pro-
duces less precise pooled effect estimates than the fixed ef-
fects model [36].
Subgroup analyses were carried out for both sexes and
two age-groups (<65 and ≥65 years). Subgroup analyses
were restricted to cohorts that could contribute to sub-
groups with a sufficient number of events. In sensitivity
analyses, cohorts with diagnoses of non-fatal events based
on self-reported physician diagnoses (ELSA and SHIP)
were excluded from analyses of primary cardiovascular
events. If not stated otherwise, analyses were conducted
with SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Multiple imputation was employed to impute the
number of missing baseline covariate values shown in
Additional file 1: Table S2. The proportion of missing
values was below 5 % for most variables, between 5 %
and 15 % on seven occasions and higher than 15 % on
three occasions (HDL cholesterol in ESTHER (37.9 %),
alcohol consumption in Tromsø (23.4 %) and GGT in
the NHANES (25.9 %)). To the best of our knowledge,
data were missing at random, which was the assumption
of the multiple imputation. Separately for the cohorts,
20 complete data sets were imputed with the SAS 9.3
procedure “PROC MI”, using the Markov chain Monte
Carlo method. Variables from the “full” model were used
for the imputation model but the outcomes were not in-
cluded. Variables were modelled continuously if possible
and the logarithm was taken if they were not normally
distributed (employed for BMI, systolic blood pressure,
HDL cholesterol, CRP, urinary albumin, serum creatinine
and GGT). This log-transformation of variables was ap-
plied in the multiple imputation process only. All multi-
variable analyses were performed in the 20 imputed data
sets and results of the individual data sets were combined
by the SAS 9.3 procedure “PROC MIANALYZE”, taking
the variation between the results of the imputed data sets
into account.
Table 2 Baseline characteristics of subjects without diabetes mellitus by very low and low HbA1c levels and multivariable adjusted
odds ratios for associations of characteristics with very low HbA1c levels. Pooled data from six cohort studies (Continued)
History of MI or stroke % 7.9 (6.9–9.1) 7.1 (6.6–7.6) 1.04 (0.87; 1.24)
Biomarkers of liver functionb
GGT U/L 44.3 (92.9) 29.9 (40.3) 1.02 (1.00; 1.04) per 10 U/L
AST U/L 24.7 (18.7) 22.0 (11.9) 1.12 (1.00; 1.26) per 10 U/L
ALT U/L 16.0 (13.4) 14.6 (11.3) 0.86 (0.75; 0.996) per 10 U/L
The table shows pooled means or proportions of baseline characteristics in the HbA1c categories and additionally the results of a multivariable logistic regression
model including all variables of the table as explanatory variables for very low HbA1c (reference: low HbA1c). Bold indicates statistically significant difference
(p <0.05). aRandom effects model reported because of statistically significant heterogeneity; bassessed in NHANES, only. ALT, alanine transferase; AST, aspartate
transferase; BMI, body mass index; GGT, gamma-glutamyl transferase; CI, confidence interval; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein;
MI, myocardial infarction
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Results
The baseline characteristics of the included subjects
without diabetes mellitus from participating cohorts are
shown in Table 1. All cohorts included an almost equal
share of men and women and mean ages were between
61.6 and 67.9 years. With few exceptions, the baseline
characteristics were similar in the cohorts. Furthermore,
the mean HbA1c was comparable across cohorts with
values between 5.4 % (36 mmol/mol) and 5.6 % (38 mmol/
mol). However, proportions of study participants with very
low and increased HbA1c levels varied substantially be-
tween the cohorts. Baseline characteristics of individuals
with very low, intermediate and increased HbA1c were
compared with the reference group with low HbA1c (see
Table 2, Additional file 1: Table S3 and Table 3, respect-
ively). The tables show pooled means or proportions of
baseline characteristics in the HbA1c categories and add-
itionally the results of the multivariable logistic regression
model including all variables from the respective table as
explanatory variables for the HbA1c difference. Very low
HbA1c levels were, in general, significantly positively asso-
ciated with variables that indicated a good prognosis for
cardiovascular outcomes and mortality; i.e. younger age,
less frequent obesity, less frequent current smoking, lower
total cholesterol and higher HDL cholesterol (Table 2).
From those variables that could potentially explain an
association of very low HbA1c levels with cardiovascular
outcomes and mortality, the following variables were
not associated with very low HbA1c levels: underweight;
subclinical inflammation; low blood hemoglobin values;
albuminuria; and high serum creatinine levels. However,
from the potentially explanatory variables, the following
variables were significantly associated with very low HbA1c
levels: non-Hispanic black race/ethnicity; high alcohol
consumption; all three biomarkers of iron deficiency; and
all three biomarkers of liver function.
In contrast to the results for very low HbA1c, increased
HbA1c levels were generally significantly associated with
characteristics that are associated with adverse cardio-
vascular outcomes and mortality; i.e. older age, other
than non-Hispanic white race/ethnicity, obesity, current
smoking, high total cholesterol, low HDL cholesterol, sub-
clinical inflammation, high serum creatinine, albuminuria,
low blood hemoglobin concentration, low transferrin sat-
uration, hypertension, a history of MI or stroke and high
ALT, with the exceptions of high alcohol consumption,
underweight, high GGT and high AST (Table 3). Results
for the intermediate group point in the same direction for
these variables as outlined for the group with increased
HbA1c but with lower effect estimates (Additional file 1:
Table S3). Overall, a consistent step-wise increase in the
burden of cardiovascular and mortality risk factors was
observed with increasing HbA1c levels in subjects without
diabetes mellitus. The exceptions were high alcohol
consumption associated with a higher proportion in
subjects with very low HbA1c levels (15.7 %) than in
subjects with low (12.0 %), intermediate (9.0 %) and in-
creased HbA1c (6.9 %), the biomarkers of liver function
(GGT, AST, ALT) and ferritin levels with highest values in
subjects with very low HbA1c levels and second highest
values in subjects with increased HbA1c (U-shaped associ-
ations) as well as erythrocyte protoporphyrin levels, which
were increased in the very low HbA1c group, only.
For the longitudinal analyses, the mean follow-up time
varied by cohort and outcome between 5.3 and 14.1 years
(Table 1, bottom). In summary, 6,769 of 28,681 study
participants died during a mean follow-up of 10.7 years
(standard deviation (SD) 3.6) of whom 2,648 died of car-
diovascular disease. Of those 20,490 study participants
without a history of MI or stroke at baseline, 2,493 expe-
rienced a primary cardiovascular event during a mean
follow-up of 8.5 years.
Figure 1 shows the dose-response relationship of HbA1c
levels with these outcomes for the “simple” model (only
age- and sex-adjusted) and “full” model (adjusted for all
variables of Table 1 except biomarkers of liver function
and iron deficiency, which were only assessed in the
NHANES). J-shaped dose-response curves are suggested
by the observed effect estimates for all-cause and cardio-
vascular mortality, whereas the association of HbA1c levels
with cardiovascular events appears to be rather linear in
both models. Hazard ratios (HR [95 % confidence inter-
val]) of the “full” model for the comparison of subjects
with very low to those with low HbA1c levels were weak
and not statistically significant for the outcomes all-cause
mortality (1.06 [0.96; 1.16]; Additional file 1: Table S4),
cardiovascular mortality (1.08 [0.79; 1.47]; Additional file
1: Table S5) and cardiovascular events (0.90 [0.76; 1.07];
Additional file 1: Table S6) and only slightly attenuated
compared to the HRs of the “simple” model.
However, these effect estimates were not adjusted for
biomarkers of liver function and iron deficiency, which
were only available in the NHANES, and the impact of
adjusting for these potential confounders can be seen for
the outcome “all-cause mortality” in Fig. 2 (the same
pattern was observed for the outcome “cardiovascular
mortality” (Additional file 1: Figure S1)). The initially
statistical significant association of HbA1c levels <4.9 %
with mortality was strongly attenuated and lost statistical
significance.
As the next step, we aimed to identify all important
confounders of the association of very low HbA1c levels
with mortality outcomes in the NHANES. To be able to
explain an increased mortality risk at very low HbA1c
levels, the confounder needs to be associated with very
low HbA1c levels and mortality in the same direction
(e.g. increases both risk for very low HbA1c levels and
mortality). The associations of all assessed variables with
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Table 3 Baseline characteristics of subjects without diabetes mellitus by increased and low HbA1c levels and multivariable adjusted
odds ratios for associations of characteristics with increased HbA1c levels. Pooled data from six cohort studies
Characteristic Unit Weighted mean or proportion (%) (95 % CI) Pooled odds ratio (95 % CI)
Increased HbA1c Low HbA1c
(6.0 to <6.5 %) (5.0 to <5.5 %)
(42 to <48 mmol/mol) (31 to <37 mmol/mol)
(reference group)
Age Years 64.5 (64.2–64.7) 62.2 (62.1–62.4) 1.41 (1.32; 1.49) per 10 years
Male sex % 47.0 (45.2–48.7) 45.0 (44.1–46.0) 0.99 (0.88; 1.11)
Race/ethnicityb
Non-Hispanic white % 44.0 70.0 Ref
Non-Hispanic black % 33.8 11.8 5.92 (4.56; 7.68)
Mexican-American % 17.8 15.1 2.11 (1.62; 2.77)
Other % 4.4 3.0 2.69 (1.69; 4.28)
School education
≤9 years % 55.6 (53.7–57.5) 45.9 (44.9–46.9) Ref
10–12 years % 32.7 (30.9–34.4) 39.1 (38.1–40.0) 0.97 (0.90; 1.04)
≥13 years % 14.6 (13.3–16.0) 19.0 (18.3–19.8) 0.99 (0.90; 1.08)
BMI category
Underweight or low weight % 3.2 (2.5–3.9) 3.9 (3.5–4.3) 0.81 (0.66; 0.99)
Optimal weight % 20.3 (18.9–21.8) 34.6 (33.7–35.5) Ref
Overweight % 45.3 (43.5–47.0) 43.6 (42.7–44.6) 1.02 (0.92; 1.14)
Obese % 32.4 (30.8–34.1) 19.2 (18.5–20.0) 1.61 (1.43; 1.81)
Smoking
Never % 44.5 (42.7–46.3) 45.8 (44.8–46.7) Ref
Former % 31.9 (30.2–33.5) 34.8 (33.9–35.7) 1.03 (0.92; 1.16)
Current % 24.1 (22.6–25.7) 20.0 (19.5–21.1) 1.73 (1.53; 1.96)
Relative alcohol consumption
Abstainer or low % 62.9 (61.1–64.7) 50.9 (49.9–51.9) Ref
Moderate % 30.5 (28.8–32.2) 37.4 (36.4–38.3) 1.05 (0.96; 1.13)
High % 6.9 (6.0–7.9) 12.0 (11.4–12.7) 0.74 (0.66; 0.83)
Vigorous physical activity % 36.0 (34.3–37.7) 42.3 (41.4–43.3) 0.93 (0.85; 1.02)
Total cholesterol mmol/L 6.08 (6.03–6.12) 6.03 (6.01–6.05) 1.18 (1.14; 1.22) per 1 mmol/L
HDL cholesterol mmol/L 1.36 (1.34–1.37) 1.52 (1.51–1.53) 0.62 (0.54; 0.71) per 1 mmol/L
Subclinical inflammation % 44.7 (42.9–46.4) 28.1 (27.2–29.0) 1.47 (1.34; 1.61)
Serum creatinine nmol/L 85.4 (84.5–86.3) 76.4 (76.0–76.8) 1.04 (1.00; 1.08)a per 10 nmol/L
Albuminuria % 21.2 (19.6–23.0) 13.3 (12.5–14.1) 1.27 (1.11; 1.45)
Hemoglobin g/dL 13.98 (13.92–14.04) 14.16 (14.14–14.19) 0.86 (0.77; 0.96)a per 1 g/dL
Biomarkers of iron deficiencyb
Ferritin μg/L 165 (170) 152 (148) 0.97 (0.91; 1.03) per 100 μg/L
Transferrin saturation % 23.8 (10.1) 26.0 (10.6) 0.85 (0.77; 0.95) per 10 %
Erythrocyte protoporphyrin μmol/L 0.94 (0.44) 0.93 (0.42) 1.02 (0.91; 1.15) per 0.5 μmol/L
Hypertension
No hypertension % 34.7 (33.1–36.4) 47.0 (46.1–48.0) Ref
Known hypertension or systolic
blood pressure ≥140 to <160 mmHg
% 49.5 (47.8–51.3) 40.2 (39.3–41.1) 1.08 (1.01; 1.15)
Systolic blood pressure ≥160 mmHg % 17.1 (15.8–18.5) 14.0 (13.4–14.7) 1.10 (1.01; 1.20)
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all-cause and cardiovascular mortality in the NHANES
are shown in Additional file 1: Table S8. By comparing
the directions of the effect estimates in Table 2 and
Additional file 1: Table S8, 11 potential confounders
were identified. Hemoglobin was exceptionally added
because there was statistically significant heterogeneity
in the meta-analysis and increasing hemoglobin concen-
tration was significantly protective for very low HbA1c
levels in the NHANES (i.e. the same direction as for mor-
tality). However, only the following eight variables actually
attenuated the strength of the association of very low
HbA1c levels with both all-cause and cardiovascular
mortality when added to an age- and sex-adjusted
model (Table 4): race/ethnicity; alcohol consumption;
BMI; hemoglobin; ferritin; erythrocyte protoporphyrin;
GGT; and ALT. Hemoglobin was the strongest confounder
but the other seven variables also contributed modestly to
an overall strong attenuation of the effect estimates because
the strength of the association increased again when they
were dropped from the final model (data not shown). Add-
ing further variables from Table 1 to the model did not lead
to further attenuation, indicating that the main confounders
of the association are included in this model. However,
excluding non-Hispanic blacks from the analysis led to
a further attenuation of the association for all-cause
mortality (HR 1.048 [0.906; 1.211]) and cardiovascular
mortality (HR 1.098 [0.885; 1.363]).
In the meta-analysis of all cohorts, HRs for the compari-
son of subjects with increased HbA1c levels and subjects
with low levels were strongly attenuated by increasing
adjustment for cardiovascular risk factors but remained
statistically significant: all-cause mortality (1.14 [1.03; 1.27];
Additional file 1: Table S4); cardiovascular mortality
(1.17 [1.00; 1.37]; P <0.05; Additional file 1: Table S5);
and cardiovascular events (1.19 [1.04; 1.37]; Additional file
1: Table S6). The covariates that were most responsible for
the attenuations were smoking, CRP and the renal func-
tion biomarkers serum creatinine and albuminuria (data
not shown).
No association of intermediate HbA1c levels with any
of the outcomes was observed in the “full” model (HR
point estimates between 1.00 and HR 1.03; Additional
file 1: Table S4–S6). Statistically significant heterogeneity
was only observed in meta-analyses on very low HbA1c
levels and mortality outcomes with associations indicating
a potentially increased mortality risk at very low HbA1c
levels (HR >1.10) in three cohorts, a potential protective
effect (HR <0.90) in one cohort and potentially no effect
(HR 0.90–1.10) in two cohorts (Additional file 1: Table
S4).
An interaction term of the variables “very low ver-
sus low HbA1c” and “age <65 versus ≥65 years” was
statistically significantly associated with the outcome
“primary cardiovascular events” (p = 0.006) but not
with all-cause mortality (p = 0.399) or cardiovascular mor-
tality (p = 0.449). Results from meta-analyses of all co-
horts stratified by age <65 years and age ≥65 years are
shown in Table 5. Observed HRs for all-cause and cardio-
vascular mortality were 1.13 [1.01; 1.27] and 1.33 [0.86;
1.27], respectively, for subjects aged ≥65 years and 0.95
[0.81; 1.12] and 0.99 [0.74; 1.33], respectively, for indi-
viduals aged 50–64 years. A stronger age-difference
was observed for the outcome “primary cardiovascular
events” with an observed HR of 1.15 [0.90; 1.46] in sub-
jects aged ≥65 years and 0.76 [0.60; 0.97] in subjects
aged 50–64 years, the latter even showing a statistically
significant protective association (Table 5). The poten-
tial age-difference was investigated in greater detail in a
sensitivity analysis in the cohort of the consortium with
the highest case numbers, the NHANES. Stratification in
5-year age-intervals in the NHANES did not show a clear
pattern towards stronger associations in older age strata
for the outcomes all-cause and cardiovascular mortality
(Additional file 1: Table S9). The outcome “primary car-
diovascular events” was unfortunately not assessed in the
NHANES. No age differences were observed for the inter-
mediate and increased HbA1c category. Furthermore, no
relevant sex differences were observed (Additional file 1:
Table S7).
Results also did not change when biomarkers of liver
function were modelled in quintiles or dichotomously
based on clinical cut-points indicating potential liver
Table 3 Baseline characteristics of subjects without diabetes mellitus by increased and low HbA1c levels and multivariable adjusted
odds ratios for associations of characteristics with increased HbA1c levels. Pooled data from six cohort studies (Continued)
History of MI or stroke % 11.8 (10.7–13.0) 7.1 (6.6–7.6) 1.32 (1.03; 1.70)a
Biomarkers of liver functionb
GGT U/L 33.5 (36.0) 29.9 (40.3) 1.02 (0.99; 1.05) per 10 U/L
AST U/L 21.5 (13.1) 22.0 (11.9) 0.81 (0.70; 0.94) per 10 U/L
ALT U/L 15.0 (11.2) 14.6 (11.3) 1.25 (1.08; 1.45) per 10 U/L
The table shows pooled means or proportions of baseline characteristics in the HbA1c categories and additionally the results of a multivariable logistic regression
model including all variables of the table as explanatory variables for increased HbA1c (reference: low HbA1c). Bold indicates statistically significant difference
(p <0.05). aRandom effects model reported because of statistically significant heterogeneity; bassessed in NHANES, only. ALT, alanine transferase; AST, aspartate
transferase; BMI, body mass index; GGT, gamma-glutamyl transferase; CI, confidence interval; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein;
MI, myocardial infarction
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Fig. 1 (See legend on next page.)
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disease (data not shown). Finally, excluding cohorts
with self-reported MI or stroke information from analyses
did not change the overall results (data not shown).
Discussion
In this individual participant data meta-analysis of six
prospective cohort studies in subjects without diabetes
mellitus, a linear association of HbA1c levels with pri-
mary cardiovascular events was observed. The observed
effect estimates for increased HbA1c levels (6.0 to <6.5 %
(42 to <48 mmol/mol)) were strongly attenuated by ad-
justment for cardiovascular risk factors (mainly by ad-
justment for smoking, inflammatory status and renal
function) but remained statistically significant for all
three outcomes (primary cardiovascular events, all-cause
mortality and cardiovascular mortality). At the lower
end of HbA1c levels, cohorts of the consortium yielded
inconsistent results for the mortality outcomes and the
pooled effect estimate was not statistically significant. In
one cohort with a pronounced J-shaped association of
HbA1c levels with all-cause and cardiovascular mortality
(NHANES), the following confounders of the association
of very low HbA1c levels with mortality outcomes were
identified: race/ethnicity; alcohol consumption; BMI; as
well as biomarkers of iron deficiency anemia and liver
function. The association of very low HbA1c levels with
mortality outcomes also lost statistical significance in
this cohort after adjusting for these confounders.
The observed increased cardiovascular risk and increased
mortality of subjects without diabetes mellitus but with
increased HbA1c (6.0 to <6.5 % (42 to <48 mmol/mol))
is in agreement with results from previous population-
(See figure on previous page.)
Fig. 1 Dose-response relationship of meta-analyzed associations of HbA1c levels with (a) all-cause mortality, (b) cardiovascular mortality and (c)
cardiovascular outcomes in subjects without diabetes mellitus with increasing adjustment for potential confounders. Crosses, point estimates of
“simple” model; circles with 95 % confidence intervals, effect estimates of “full” model. Reference group: HbA1c 5.0 to <5.5 % (31 to <37 mmol/mol)
Fig. 2 Dose-response relationship of HbA1c levels with all-cause mortality in subjects without diabetes mellitus in the NHANES with (a) adjustment for
age and sex and (b) adjustment for all potential confounders (“full” model including biomarkers of iron deficiency and liver function). Solid
line, estimation; points in solid lines, knots; horizontal dashed line, null effect value (hazard ratio = 1); curved dashed lines, boundaries of 95 %
confidence interval band of estimation
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based cohort studies [5, 6, 11, 12, 16–18, 37–40]. This
consistent finding from observational studies is sup-
ported by the fact that coronary atherosclerosis and
plaque vulnerability are advanced in subjects with in-
creased HbA1c levels even if they are below the thresh-
old for a diabetes diagnosis [41]. However, we observed
a strong attenuation of effect estimates by adjustment
for conventional cardiovascular risk factors, which was
also observed by others [5–7]. This attenuation could
be explained by confounding mostly by smoking, CRP
and renal function, factors which were associated with
increased HbA1c. The fact that smokers have higher
HbA1c levels than non-smokers or ex-smokers was also
observed in another consortium of cohort studies [42].
Nevertheless, effect estimates remained statistically signifi-
cant in comprehensively adjusted models, which could
indicate a small independent contribution of impaired
glucose metabolism, below the diagnostic threshold for
diabetes mellitus, to the development of cardiovascular
disease. However, the small effect estimates could also
be simply due to residual confounding because it is impos-
sible to perfectly adjust for all cardiovascular risk factors
in observational studies. The majority of randomized
controlled trials (RCTs) in non-diabetic subjects with
increased HbA1c failed to observe significant effects when
aiming to reduce the cardiovascular risk and mortality of
these individuals [43]. However, the short average follow-
up time of 3.75 years was a limitation of previous trials
and further RCTs, with larger sample size and longer
follow-up are required to explore the efficacy of non-drug
and drug-based approaches to reduce the cardiovascular
risk of non-diabetic subjects with increased HbA1c [43].
With respect to very low HbA1c in subjects without
diabetes mellitus, this meta-analysis of the CHANCES
consortium yielded inconsistent results for the outcomes
all-cause and cardiovascular mortality and a consistent,
albeit statistically non-significant decreased risk for
primary cardiovascular events in subjects with an
HbA1c <5 % (<31 mmol/mol). The latter contrasts with
the meta-analysis of the ERFC that observed a significantly
increased cardiovascular risk in subjects with an HbA1c
<4.5 % (<26 mmol/mol) (HR 1.23 [1.02; 1.50]) compared
with subjects with an HbA1c of 5 to <5.5 % (31 to
<37 mmol/mol). However, the result for this HbA1c
category was only based on 127 cardiovascular events
from 24 studies. Our meta-analysis included 159 car-
diovascular events from five studies in the lowest
HbA1c category (<5 % (<31 mmol/mol)). Low numbers
of events from single studies can affect the model sta-
bility and can result in high point estimates with wide
confidence intervals. Therefore, despite the overall
large sample size of this meta-analysis and the meta-
analysis of the ERFC, the results for the lowest HbA1c
category of both could be biased by low sample sizes
and be random findings.
Because many previous studies [13–18] have observed
an increased mortality of non-diabetics with very low
HbA1c levels and this was also found in two out of six of
the cohorts included in our meta-analysis (NHANES and
ESTHER), we aimed to explore potential explanations in
Table 4 Attenuation of strength of the association of very low HbA1c levels (<5 % (<31 mmol/mol)) with all-cause and cardiovascular
mortality by adding potential confounders to the “simple” model in the NHANES
Model HR (95 % CI)a Attenuation for
both outcomesAll-cause mortality CV mortality
Age + sex (“simple” model) 1.201 (1.057; 1.328) 1.221 (1.005; 1.409) N/A
Age + sex + race/ethnicity 1.184 (1.042; 1.341) 1.203 (0.989; 1.453) Yes
Age + sex + alcohol consumption 1.192 (1.051; 1.353) 1.212 (1.000; 1.469) Yes
Age + sex + BMI 1.172 (1.033; 1.330) 1.197 (0.988; 1.450) Yes
Age + sex + physical activity 1.208 (1.065; 1.370) 1.231 (1.016; 1.491) No
Age + sex + hemoglobin 1.166 (1.027; 1.324) 1.188 (0.980; 1.440) Yes
Age + sex + ferritin 1.193 (1.052; 1.354) 1.211 (0.999; 1.467) Yes
Age + sex + total cholesterol 1.192 (1.051; 1.353) 1.226 (1.012; 1.486) No
Age + sex + erythrocyte protoporphyrin 1.177 (1.036; 1.337) 1.208 (0.995; 1.466) Yes
Age + sex + GGT 1.178 (1.038; 1.337) 1.206 (0.995; 1.462) Yes
Age + sex + AST 1.199 (1.057; 1.361) 1.222 (1.009; 1.481) No
Age + sex + ALT 1.199 (1.057; 1.360) 1.215 (1.003; 1.472) Yes
Age + sex + race/ethnicity + alcohol consumption + BMI
+ ferritin + erythrocyte protoporphyrin + GGT + ALT
1.081 (0.950; 1.230) 1.106 (0.909; 1.345)
All variables of Table 1 1.103 (0.968; 1.256) 1.120 (0.921; 1.363)
aReference group: low HbA1c (5.0 to <5.5 % (31 to <37 mmol/mol)). ALT, alanine transferase; AST, aspartate transferase; BMI, body mass index; CV, cardiovascular;
GGT, gamma-glutamyl transferase; HR, hazard ratio, N/A, not applicable
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Table 5 Age-stratified analyses of the associations of HbA1c levels with mortality and cardiovascular outcomes in subjects without diabetes mellitus
Outcome/stratum Very low HbA1c (<5.0 %)
(<31 mmol/mol)
Low HbA1c (5.0 to <5.5 %)
(31 to <37 mmol/mol)
Intermediate HbA1c (5.5 to <6.0 %)
(37 to <42 mmol/mol)
Increased HbA1c (6.0 to <6.5 %)
(42 to <48 mmol/mol)
ntotal ncases IR
a HR (95 % CI)b ntotal ncases IR
a HR ntotal ncases IR
a HR (95 % CI)b ntotal ncases IR
a HR (95 % CI)b
All-cause mortality
50–64 years 1,688 205 10.0 0.95 (0.81; 1.12) 6,563 769 9.8 Ref 6,336 761 10.1 0.91 (0.82; 1.01) 1,514 272 15.8 1.18 (1.02; 1.37)
≥65 years 632 314 53.3 1.13 (1.01; 1.27) 3,779 1,556 42.6 Ref 4,767 1,978 43.3 1.06 (0.99; 1.13) 1,413 723 50.4 1.14 (1.04; 1.26)
Cardiovascular mortality
50–64 years 1,218 61 3.7 0.99 (0.74; 1.33) 4,824 210 3.2 Ref 4,915 220 3.4 0.93 (0.76; 1.13) 1,194 78 5.3 1.14 (0.87; 1.50)
≥65 years 548 155 28.4 1.33 (0.86; 2.04)c 2,574 589 20.9 Ref 3,343 753 21.2 1.07 (0.82; 1.39)c d 1,035 249 24.2 1.18 (1.01; 1.38)
Cardiovascular events
50–64 years 1,276 77 5.1 0.76 (0.60; 0.97) 5,626 456 8.1 Ref 5,470 507 9.6 1.09 (0.96; 1.25) 1,165 114 10.6 1.18 (0.95; 1.47)
≥65 years 409 82 22.4 1.15 (0.90; 1.46) 2,491 488 22.8 Ref 3,207 598 23.0 0.99 (0.88; 1.12) 846 171 26.7 1.19 (0.98; 1.45)
Bold indicates statistically significant difference (p <0.05). aIR, incidence rate per 1,000 person-years. The IR is the weighted mean of the IRs of the individual studies (weighted by sample size); badjusted for age, sex,
race/ethnicity, BMI, education, smoking, physical activity, alcohol consumption, total cholesterol, HDL cholesterol, CRP, hemoglobin, serum creatinine, albuminuria, hypertension and history of CVD; crandom effects
model result reported due to statistical significant heterogeneity. CI, confidence interval; HbA1c, glycated hemoglobin; HR, hazard ratio; IR, incidence rate; n, sample size
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the NHANES because this study assessed all relevant vari-
ables that could confound the association of very low
HbA1c levels and mortality. The strongest confounder was
anemia, which was expected because hemoglobin and
HbA1c concentrations are correlated [32]. The biomarkers
of iron deficiency ferritin and erythrocyte protoporphyrin
were also identified as confounders but whether iron-
deficiency anemia, non-iron-deficiency anemia or both are
of relevance for very low HbA1c levels needs to be deter-
mined by further studies because the underlying biology is
complex [21]. Non-Hispanic black race/ethnicity was also
an expected confounder because African-Americans, com-
pared with white Americans, have a different hematologic
profile including lower hemoglobin values [26]. High
alcohol consumption and biomarkers of liver disease
were further confounders, which could be explained by
an inhibition of the gluconeogenesis in the liver [23]
and a shortening the red blood cell lifespan. Very low
HbA1c values can simply originate from everything that
reduces the red blood cell lifespan because some time
is needed for glucose and hemoglobin to interact and
form glycosylated hemoglobin [24]. BMI also played a
role but not as expected. Underweight was not associated
with very low HbA1c levels and obesity was protective for
very low HbA1c levels. The confounding for mortality
could result from obesity that has been found to be pro-
tective for mortality at older age [44]. However, it is yet
unclear whether this “obesity paradox” is due to statistical
biases or has a plausible underlying biology [44]. In sum-
mary, from the hypotheses listed in the introduction, only
subclinical inflammation and renal function were not con-
firmed as confounders for the association of very low
HbA1c levels and mortality in the NHANES.
The first and, to our knowledge, only other study that
aimed to discover potential mechanisms that could ex-
plain an increased risk of mortality in subjects with very
low HbA1c levels did not find any attenuation of the
strength of the association of very low HbA1c levels
(<5.0 % (<31 mmol/mol)) with all-cause mortality after
additional adjustment for diseases, weight measures,
education, alcohol consumption, physical activity, smoking,
hemoglobin, red blood cell mean corpuscular volume,
fibrinogen and leukocyte count [17].
In our meta-analysis, a significant interaction was ob-
served between very low HbA1c levels and age for the out-
come “primary cardiovascular events”. To our knowledge,
this is a novel finding but since it is from a subgroup
analysis, further studies are required to corroborate this
interaction with age. There is room for doubts, because
this interaction was not significant for the other out-
comes “all-cause mortality” and “cardiovascular mortal-
ity” and stratification by 5-year intervals in the NHANES
also showed that there was no age-difference in the associ-
ation of very low HbA1c levels with fatal outcomes.
When interpreting our results, the following limita-
tions and strengths should be considered. The main
limitation of this meta-analysis is the observational na-
ture of the included prospective cohort studies. Despite
adjustment for known potential confounders, we cannot
rule out the possibility that the observed associations are
confounded by other unmeasured factors (e.g. biomarkers
of liver function and iron deficiency in cohorts other than
NHANES and other unmeasured factors known to affect
HbA1c assay test results, such as participation in endur-
ance sport, late pregnancy and major blood loss [45]) or
residual confounding by variables that could have been
more precisely measured (e.g. physical activity). It can be
expected that some residual confounding is present in the
data and observed small effect sizes for increased HbA1c
levels could be due to residual confounding despite the
observed statistical significant associations. Furthermore,
it is possible that people with pre-diabetes at baseline de-
veloped manifest diabetes mellitus in the first years of
follow-up and experienced a cardiovascular outcome or
death in later follow-up due to diabetes and not pre-
diabetes. However, diabetes incidence information was not
collected for this analysis and this could not be further
elucidated.
Other limitations include the fact that non-fatal MI
and stroke information was solely based on self-reported
information in two cohorts but the overall results did not
change when these cohorts were excluded in sensitivity
analysis. Furthermore, other glucose measures (i.e. fasting
glucose or measures based on an oral glucose tolerance
test) were not included, which could have yielded different
results. Furthermore, HbA1c was measured once whereas
measurements at different time-points could have cor-
rected better for intra-individual variation and random
measurement errors. In addition, different HbA1c assays
were applied in the cohorts but they were all traceable to
the assay of the DCCT trial and therefore comparable.
Strengths of our study include the variety of cohorts
from all over Europe and the United States, the overall
large size enabling subgroup analyses for age and sex,
almost complete mortality registry-based follow-ups
and the common statistical analysis strategy. A particular
advantage over previous studies is the adjustment for a
large number of cardiovascular risk factors including bio-
markers of inflammation, renal function, lipid metabolism,
liver function and anemia.
Conclusions
In this meta-analysis of subjects without diabetes mellitus
from six prospective cohort studies a linear association
of HbA1c levels with primary cardiovascular events was
observed. The observed effect estimates for increased
HbA1c levels were strongly attenuated by adjustment
for cardiovascular risk factors for all three outcomes
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(primary cardiovascular events, all-cause mortality and
cardiovascular mortality). The cohorts yielded incon-
sistent results for the associations of very low HbA1c
levels with mortality outcomes. For cardiovascular and
all-cause mortality, the observed small effect sizes at
both the lower and upper end of HbA1c distribution do
not support the notion of a J-shaped association of
HbA1c levels because a certain degree of residual con-
founding was likely present in the meta-analyses, which
could not be adjusted for iron deficiency anemia and
liver function as they were not assessed in most cohorts.
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